Dithranol
Brand names: Dithrocream, Micanol
Dithranol (anthralin) is a topical antiproliferative agent used for chronic plaque psoriasis, often as short-contact therapy.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It reduces the excessive epidermal proliferation seen in psoriasis, with effects linked to inhibition of keratinocyte turnover and generation of reactive oxygen species in the skin.
Prescribing in practice
- Dithranol is irritant and can burn normal skin, so apply it carefully to plaques only and protect surrounding healthy skin, washing it off after the prescribed contact time.
- It stains skin, hair, clothing, bedding and surfaces, which limits acceptability and adherence.
- Avoid use on the face, flexures, genitals and acutely inflamed or unstable psoriasis.
Monitoring
Monitor clinically for plaque response and for irritation or burning of surrounding normal skin.
Counselling the patient
- Apply only to the thickened plaques, keep it off normal skin, and wash it off after the time you have been told.
- Expect staining of skin, hair, clothes and the bath; protect surfaces and use older bedding and towels.
- Stop and seek advice if the surrounding skin becomes sore or burnt.
Evidence & guidelines
Dithranol short-contact therapy is a long-established treatment for chronic plaque psoriasis supported by NICE psoriasis guidance.
Reference: SmPC Dithrocream; BAD Psoriasis Guideline 2017 (updated 2022); NICE CG153 (Psoriasis); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD